SCHEMBL3146496

SCHEMBL3146496

O=c1[nH]c2ccccc2n1C1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.83
CHRM4 P08173 2/20 0.83
CHRM1 P11229 2/20 0.83
CHRM3 P20309 1/20 0.83
OPRM1 P35372 9/20 0.71
OPRL1 P41146 8/20 0.71
OPRK1 P41145 7/20 0.71
SLC18A3 Q16572 1/20 0.67
OPRD1 P41143 3/20 0.64
ALDH1A1 P00352 1/20 0.64
MAPK1 P28482 1/20 0.64
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
SIRT2 Q8IXJ6 1/20 0.58
ABL1 P00519 1/20 0.58
RIN1 Q13671 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3142425 0.98 CHRM1 (0.81) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL4084782 0.95 CHRM1 (0.76) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL319049 0.91 CHRM1 (0.70) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL4919819 0.91 CHRM1 (1.00) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL4572894 0.91 CHRM1 (1.00) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL27056694 0.91 CHRM1 (1.00) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL3895786 0.86 CHRM1 (0.92) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL22724773 0.86 CHRM1 (0.64) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL44492 0.85 CHRM1 (0.63) CHRM2CHRM4CHRM1CHRM3OPRM1
SCHEMBL8863641 0.85 CHRM1 (0.63) CHRM2CHRM4CHRM1CHRM3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951046-B2 TRPA1 modulators ALGOMEDIX, INC. (US) 2018-04-24 US disclosed
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-02-22 US disclosed
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-22 US disclosed
US-20170001983-A1 TRPA1 MODULATORS ALGOMEDIX, INC. 2017-01-05 US disclosed
US-8236965-B2 Benzimidazole derivatives and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-08-07 US disclosed
US-20100286122-A1 CGRP Antagonist Salt MERCK SHARP & DOHME CORP. 2010-11-11 US disclosed
US-7687529-B2 Substituted propylamine derivatives and methods of their use WYETH LLC (US) 2010-03-30 US disclosed
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2009-07-02 US disclosed
US-7495110-B2 Benzimidazole derivatives and their use as GnRH antagonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US disclosed
EP-1934178-A2 SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE Wyeth (US) 2008-06-25 EP disclosed
WO-2007041257-A2 SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2007-04-12 WO disclosed
US-20070072928-A1 treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one WYETH (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072928-A1 treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one TPH1, HTR1A, HTR5A CHRM2 658/4885CHRM4 1150/4885CHRM1 414/4885
US-20100286122-A1 CGRP Antagonist Salt KCNJ2, KCNN3, KCNH2 CHRM2 1719/4885CHRM4 1490/4885CHRM1 1236/4885
US-20170001983-A1 TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 CHRM2 1049/4885CHRM4 691/4885CHRM1 1068/4885
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS MC1R, CALCRL, BDKRB2 CHRM2 364/4885CHRM4 687/4885CHRM1 365/4885
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF NAMPT, NQO2, NNMT CHRM2 2054/4885CHRM4 1699/4885CHRM1 1584/4885
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament GNRHR, FSHR, KISS1R CHRM2 377/4885CHRM4 503/4885CHRM1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.